Metabolic Syndrome: when science meets prevention
On 23rd November 2021, Quality Assistance hosted its third INNOVATION scientific congress at the CEME in Charleroi, in partnership with A-Mansia Biotech. This edition focused on metabolic syndrome, a growing public health concern linked to lifestyle changes, urbanisation, and genetic predispositions.
Metabolic syndrome is not a single disease but a cluster of conditions—including abdominal obesity, high blood pressure, raised blood sugar, and abnormal cholesterol levels—that significantly increase the risk of type 2 diabetes, cardiovascular disease, and stroke. Often silent, it may remain undetected can go unnoticed for years, making prevention and early detection essential.
The congress brought together a diverse group of experts from the pharmaceutical, medical, and research sectors to share insights on the origins, mechanisms, and potential interventions for this complex condition.
Following an opening speech by Véronique Halloin, General Secretary of the FNRS, discussions ranged from gut microbiota and inflammation to insulin resistance and oxidative stress. The event also highlighted the importance of cross-disciplinary collaboration in developing effective prevention strategies and therapeutic solutions.
What set this congress apart was its emphasis in anticipating disease rather than reacting to it. The discussions underscored the value of scientific innovation not only in treating metabolic syndrome but also in identifying risk factors early and promoting healthier lifestyles.
At Quality Assistance, we believe innovation should not only treat disease but also help prevent it. By supporting events like this congress, we aim to foster dialogue between disciplines and keep the human experience at the heart of scientific progress.
You must accept functional cookies to play the video. Change settings
With the support of A-Mansia Biotech and FNRS